


1:00pm – 1.20pm	Welcome & official opening
	Rosanne Hyland, Chief Operating Officer, AusBiotech
	Hon Joe Szakacs MP , Minister for Trade and Investment, Local Government and Veterans' Affairs, South Australian Government
1.20pm – 1.40pm	Keynote
	Investing in health: an angel's journey
	The angel investor community is becoming increasingly sophisticated and is a serious source of capital, fueling the growth of startups and contributing to high growth sectors. The formation of an ecosystem of investors that have knowledge of the healthcare sector is a relatively recent development and creates more formal connections between entrepreneurs and angels. This session will cover recent developments in the angel investor community from the perspective of Medical Angels and provide guidance to companies on how to navigate the angel investor landscape and assess the right partners to work with. Chair: Rosanne Hyland, Chief Operating Officer, AusBiotech Dr. Amandeep Hansra, Lead Investor & Co-Founder, Medical Angels
1.40 pm – 2.40pm	Investee presentations
	 Chair: Rosanne Hyland, Chief Operations Officer, AusBiotech Dr Mary Beth Brinson, Chief Executive Officer, Cyban Dr Shieak Tzeng, Co-CEO & Founder, Wellumio Jack Brown, Corporate Development Director, LBT Innovations (ASX:LBT) Tom Spurling, Managing Director, AlphaRET (ASX:EYE)
2.40pm – 3.00pm	Keynote
	Deep tech investing and its role in healthcare
	Deep tech has seen an exponential rise in past decade, with an increasing number of investors moving into the space. Deep tech's share of venture capital investment has remarkably doubled over the past decade, now accounting for 20% of the total, up from just 10% ten years earlier (source: Boston Consulting Group, November 2023). With a prime focus on developing technology solutions based on substantial mathematical,
	scientific or engineering challenges, deep tech is an umbrella definition that includes, amongst others, agri-tech, food tech, clean tech, artificial intelligence and machine learning. It also includes some life science companies, with the term applied to businesses whose objective is to find innovative solutions using novel technologies.



	In this keynote address, Alex Romero will discuss the deep tech healthcare ecosystem, the outstanding research emanating from Australia's laboratories, and our nation's potential as a global deep tech hub. Chair: Rosanne Hyland, Chief Operating Officer, AusBiotech Alex Romero, Associate, Main Sequence
3.00pm – 3.20pm	Afternoon tea
3.20pm – 3.50pm	Panel discussion
	Ice melts, markets thaw: 2024 medtech investment insights
	As the market is emerging from its icy grip from the last couple of years, we'll navigate the current Australian and international investment landscape. Catering to both newcomers and specialists this session will highlight the hottest opportunities and areas to approach with caution, drawing from the experience of our seasoned panellists. We will explore what makes a successful investment, what's required on the journey and hear how they try to steer clear of potential treacherous terrain. Chair: Sarah Meibusch, Partner, OneVentures
	Panellists: Dr Chris Nave, Founding Partner and Managing Director, Brandon Capital Dr Steve Burnell, Managing Director, Tenmile Fredrik Nyberg, Managing Director, MedTech Innovator Asia Pacific Rohan Gray, Portfolio Manager – Australian VC, Artesian Venture Partners
3.50pm – 4.50pm	Investee presentations
	Chair: Sarah Meibusch, Partner, OneVentures
	 Tony Simula, Managing Director & Chief Executive Officer, TekCyte Mark Roe, Chief Executive Officer, Managing Director, Fusetec Dr Simon Graindorge, Chief Operating Officer, OncoRes Medical David Hoey, Chief Executive Officer, Vaxxas
4.50pm – 5.10pm	Keynote
	Driving successful medtech internationalisation through medtech investing
	As a global healthcare investment firm with more than \$8 billion in funds under management, ARCHIMED is one of the latest international healthcare investors to set up shop in Australia.
	With a portfolio of 34 companies (25 active and 9 exists), ARCHIMED's investments span 7 key healthcare subsectors: biopharma products, medtech, in vitro diagnostics, consumer health, healthcare IT, life science tools and biological services, and pharma services. ARCHIMED invests between 10 million and 1 billion Euros in leading companies across Europe, North America, Latin America, and most recently APAC, with a focus on supporting small to mid-cap companies



	in their internationalisation efforts, capacity increase, product range expansion, and acquisitions.
	Following investments, ARCHIMED typically focuses on growth and business development-related priorities, such as innovation, internationalisation, acquisitions or capacity expansion.
	In this keynote, hear from Rowena Gracey, Director, ARCHIMED, as she discusses Australia's reputation as a hotbed for innovation, ARCHIMED's healthcare investments that have successfully internationalised, and what could be done differently to help Australian innovations expand globally.
	Chair: Rhenu Bhuller, Global Investment Lead, AusBiotech
	Rowena Gracey, Director, ARCHIMED
5.10pm – 5:25pm	Keynote
	ASX Update: The why, when, how and who of listingand what comes after A quick blast of why list on ASX, when is the right time, how it works, who to connect with plus what ASX provides to support companies post listing to tell their story and reach investors.
	Chair: Rhenu Bhuller, Global Investment Lead, AusBiotech
	Ajita Tynan, Manager, Listed Company Services & Sasha Conoplia, Manager, Listings, ASX
5.25pm – 5:30pm	Closing remarks
	Rosanne Hyland, Chief Operating Officer, AusBiotech
5:30pm – 7.00pm	AusMedtech 2024 Welcome reception Sponsored by FB Rice